Correlation of the Serum bFGF Level with MDS Typing, Serum IL-32 Level and Prognosis

Abstract

To investigate the correlation of serum bFGF level with MDS typing, serum IL-32 and prognosis. A total of 62 patients with myelodysplastic syndromes admitted in our hospital from April of 2014 to April of 2017 were enrolled in MDS group. And 50 healthy people who received healthy physical examination in our hospital were selected as the control group at the same period. According to the type of disease, the MDS group was divided into 4 subgroups: A, B, C, D. the serum levels of bFGF, and IL-32 were detected, and the prognosis of patients with different MDS types was evaluated. The serum levels of bFGF and IL-32 in 4 subgroups of MDS were higher than those in the control group (P<0.05). the serum level of bFGF and IL-32 was not significanty different between subgroup A and B (P>0.05), and the serum levels bFGF and IL-32 also was no significantly different between subgroup C and D (P>0.05), but the serum levels of bFGF and IL-32 in subgroup C and D were significantly higher than those in subgroup A and B (P<0.05). The total efficiency of clinical treatment was not significantly different between subgroup A and B (P>0.05),but significantly higher than that in the other 2 subgroups (P<0.05). The serum levels of bFGF and IL-32 in MDS patients were significantly higher than that in the normal controls, while the serum levels of bFGF and IL-32 in RAEB and RAEB-t subtypes were significantly higher than that in RA and RAS. The changes of serum bFGF and IL-32 levels are positively correlative.